Epinephrine injections used to treat severe allergic reactions have been recalled because the manufacturer could not assure the products were sterile, the U.S. Food and Drug Administration said.
The recall covers injectable epinephrine, a drug that reverses life-threatening anaphylaxis within minutes. The FDA did not identify a specific bacterial or fungal contamination in the affected lots, only a failure to confirm sterility.
Sterility is not optional for drugs injected into the body. A contaminated batch can cause bloodstream infections, sepsis, or death, particularly in patients whose immune systems are already under strain.
Epinephrine is among the most time-sensitive drugs in medicine. Patients with food allergies, insect sting allergies, or medication reactions rely on it as a first-line rescue treatment, often carrying auto-injectors at all times.
Manufacturing these products involves multiple stages, from raw ingredient sourcing to final filling and sealing. Each step introduces a chance for microbes to enter the supply chain, according to experts who study pharmaceutical production.
The recall adds to a pattern of sterility-related problems in the drug industry. In recent years, the FDA has flagged repeated issues at compounding pharmacies and large manufacturing plants, including mold and bacteria found in supposedly sterile facilities.
Recalls carry financial weight as well as health risks. Companies must pull product from shelves, notify distributors and patients, and often shut down production lines for investigation and cleaning. The costs can run into the millions.
For patients, the immediate concern is access. Epinephrine has no substitute when a reaction turns severe. A shortage triggered by a recall can leave people scrambling for replacement doses, sometimes across state lines or through emergency rooms.
The FDA advises patients to check lot numbers on their epinephrine injectors and contact their pharmacy or the manufacturer if their product is affected. Patients should not stop carrying epinephrine because of the recall.
The agency said it is working with the manufacturer to determine the scope of the problem and prevent further distribution of potentially unsafe lots. It did not say how many units were affected or whether any injuries had been reported.
The recall serves as a reminder that sterility failures can happen at any point in a complex manufacturing chain, and that oversight of those steps remains a persistent challenge for regulators.
